Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults.

ABSTRACT:

Background

In spring 2020, at the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Europe, we set up an assay system for large-scale testing of virus-specific and neutralising antibodies including their longevity.

Methods

We analysed the sera of 1655 adult employees for SARS-CoV-2-specific antibodies using the S1 subunit of the spike protein of SARS-CoV-2. Sera containing S1-reactive antibodies were further evaluated for receptor-binding domain (RBD)- and nucleocapsid protein (NCP)-specific antibodies in relation to the neutralisation test (NT) results at three time points over six months.

Results

We detect immunoglobulin G (IgG) and/or IgA antibodies reactive to the S1 protein in 10.15% (n = 168) of the participants. In

SUBMITTER: Wagner A 

PROVIDER: S-EPMC9037317 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature